Literature DB >> 17050384

Community preparedness for HIV vaccine trials in the Democratic Republic of Congo.

John Olin1, Jacques Kokolamami, Francois B Lepira, Kashamuka Mwandagalirwa, Bavon Mupenda, Michel Lubaki Ndongala, Suzanne Maman, Robert Bollinger, Jean Nachega, John Mokili.   

Abstract

This paper reports on an assessment of community preparedness for HIV vaccine trials in the Democratic Republic of Congo. Formative research was conducted in the capital city of Kinshasa during the period October 2003 to March 2004 to answer questions pertinent to planning trials of a preventive HIV vaccine and to identify related issues. Twenty-seven in-depth interviews and two focus groups were held with potential trial participants and community leaders. Data was collected on the subjects of vaccines, HIV/AIDS and sexual behaviour, and an HIV vaccine. The study also sought to identify factors that motivate a person to volunteer for a vaccine trial or which are disincentives to participation, along with preparedness of the larger community for trials. Personal concerns for health and for the impact of the epidemic on families and country were common motivations for participation. The danger of an experimental vaccine and the stigma of a positive HIV antibody test as the result of vaccination are major concerns and disincentives. The health, educational, and local non-governmental sectors are identified as having important roles to play in assuring preparedness for trials, although significant challenges exist to achieving community preparedness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050384     DOI: 10.1080/13691050600888434

Source DB:  PubMed          Journal:  Cult Health Sex        ISSN: 1369-1058


  6 in total

1.  Beyond clinical trials: social outcomes of structured stakeholder engagement in biomedical HIV prevention trials in China.

Authors:  Chuncheng Liu; Kathrine Meyers
Journal:  Cult Health Sex       Date:  2019-11-08

2.  How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania.

Authors:  Andrew Vallely; Shelley Lees; Charles Shagi; Stella Kasindi; Selephina Soteli; Natujwa Kavit; Lisa Vallely; Sheena McCormack; Robert Pool; Richard J Hayes
Journal:  BMC Med Ethics       Date:  2010-06-13       Impact factor: 2.652

3.  Relationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccination.

Authors:  April M Young; Daniel S Halgin; Jennifer R Havens
Journal:  AIDS Care       Date:  2015-03-02

4.  Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa?

Authors:  Andrew Vallely; Ian R Hambleton; Stella Kasindi; Louise Knight; Suzanna C Francis; Tobias Chirwa; Dean Everett; Charles Shagi; Claire Cook; Celia Barberousse; Deborah Watson-Jones; John Changalucha; David Ross; Richard J Hayes
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

5.  Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation.

Authors:  April M Young; Daniel S Halgin; Ralph J DiClemente; Claire E Sterk; Jennifer R Havens
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

6.  What motivates or demotivates injecting drug users to participate in hypothetical HIV vaccine efficacy trials? A qualitative study from urban Tanzania.

Authors:  Masunga K Iseselo; Edith Am Tarimo; Eric Sandstrom; Asli Kulane
Journal:  East Afr Health Res J       Date:  2020-11-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.